查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1701345

化療嗜中性白血球低下症治療市場規模、佔有率、趨勢分析報告：按療法、藥物、給藥途徑、通路、地區和細分市場進行預測，2025 年至 2030 年

Chemotherapy-induced Neutropenia Treatment Market Size, Share & Trends Analysis Report By Treatment (Growth Factors, Antibiotics), By Drug, By Route of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 195 Pages | 商品交期: 2-10個工作天內

價格

化療引起的嗜中性白血球低下症(CIN) 治療市場的成長和趨勢

根據Grand View Research, Inc.的最新報告，全球化療引起的嗜中性白血球低下症治療市場預計到2030年將達到15.1億美元，2025年至2030年期間的複合年成長率為-0.48%。

這種下降可能是由於多種因素造成的，包括標靶癌症療法和免疫療法的採用率增加，與傳統化療相比，這些療法降低了化療引起的嗜中性白血球低下症的發生率。隨著精準醫療的進步，腫瘤學家擴大轉向最大限度減少骨髓抑製作用的治療方法，從而減少對 CIN 治療的需求。然而，居家醫療治療方法和自我治療的興起也為製藥公司提供了開發方便用戶使用型配方以提高患者便利性的機會。

化療引起的嗜中性白血球低下症是癌症治療的一個嚴重副作用，對接受化療的患者構成重大風險。隨著癌症發病率不斷上升，對有效 CIN 治療的需求正在推動醫療保健領域的顯著成長。開發人員正在利用治療方法進步、新藥開發和改進的患者照護解決方案來解決這一重大疾病。市場對生長因子、抗生素、抗真菌藥物和其他支持療法的投資正在增加，以確保更好地管理 CIN 並減少相關併發症。

為了有效對抗 CIN，生長因子在刺激白血球生成和降低兒童感染疾病風險方面發揮關鍵作用。顆粒細胞增生因子(G-CSF) 是主要的治療選擇，可促進嗜中性白血球恢復並最大限度地減少化療延遲。安進公司 (Amgen Inc.)、山德士 (Sandoz)、梯瓦製藥工業有限公司 (Teva Pharmaceutical Industries Ltd.)、Coherus BioSciences、Viatris Inc. 和 Biocon Biologics Inc. 等主要製藥公司處於 G-CSF 開發的前沿。

Filgrastim是一種廣泛使用的 G-CSF 重組形式，可促進嗜中性白血球的恢復。長效非格Filgrastim，Pegfilgrastim，可以減少給藥頻率，而Pegfilgrastim已被證實可以提供持續的嗜中性白血球刺激。 Efrapegrastim 是一種新型長效 G-CSF，可有效預防 CIN，而 efvemarenograstim alfa 是一種正在開發的增強嗜中性白血球支持的下一代療法。此外，粒細胞巨噬細胞集落刺激因子 (GM-CSF) 在嗜中性白血球恢復方面具有治療潛力。輝瑞公司、Spectrum Pharmaceuticals, Inc.、Evive Biotech 和 G1 Therapeutics, Inc. 等主要市場參與企業正積極投資研發，以提高這些治療的療效。

然而，儘管使用了生長因子，CIN 患者仍然容易受到細菌和真菌感染，因此使用預防性和治療性抗生素至關重要。預防性抗生素在預防高風險患者感染方面發揮重要作用，而如果發生感染疾病則使用治療性抗生素。同樣，抗真菌藥物有助於對抗機會性感染疾病，確保全面的患者照護。總的來說，這些治療方法形成了一個多層次的防禦系統，以抵禦 CIN 帶來的風險。預防性抗生素作為預防措施，可降低嗜中性白血球低下症患者的感染率，而治療性抗生素則有助於對抗因免疫系統減弱而引起的細菌感染疾病。抗真菌藥物還可以增強對侵襲性真菌感染疾病的防禦，這種感染對於接受化療的患者來說可能是危及生命的。

除了這些傳統的治療方案外，粒細胞輸注和免疫調節劑等較新的治療方法也受到關注，成為治療嚴重嗜中性白血球低下症的潛在解決方案。持續的研究和創新有望提高這些治療方法的有效性和可近性，進一步加強市場環境。 CIN 治療市場分為品牌藥物和生物相似藥。雖然品牌藥物因其既定的療效而繼續佔據主導地位，但生物相似藥因其成本效益和日益普及而迅速普及。隨著監管部門核准的擴大和醫療服務可及性的改善，生物相似藥的選擇越來越廣泛，使更多患者能夠從先進的療法中受益，而無需承擔昂貴的品牌藥物的經濟負擔。

隨著新藥的開發，藥物輸送治療方法也不斷發展。腸外給藥仍是 CIN 治療的黃金標準，建議透過靜脈注射G-CSF 和抗生素來獲得快速有效的結果。然而，口服預防性抗生素和免疫調節劑在門診環境中提供了便利，並且越來越受歡迎。這些管理上的變化與整個醫療保健領域的趨勢一致，即改善患者的就醫機會並減少對醫院進行慢性病管理的依賴。

隨著全球癌症負擔不斷增加，CIN治療市場預計將大幅擴大。生物相似藥的日益普及、藥物開發的持續進步以及創新治療方法的持續研究正在共同塑造 CIN 管理的未來。隨著認知的提高、治療通訊協定的改進以及對支持性護理的投入增加，CIN 治療的未來可能會取得重大進展。這些發展不僅改善了患者的治療效果，而且促進了全球醫療保健解決方案的整體進步。

化療嗜中性白血球低下症治療市場報告重點

  • 根據治療方法，生長因子部分在 2024 年佔據了市場主導地位。該部分的主導地位可歸因於其經過驗證的功效、在癌症治療方案中的廣泛採用以及生物學名藥的持續進步。
  • 2024 年，生物相似藥在藥物類型領域佔據市場領先地位，這得益於監管部門核准的不斷增加、成本效益的提高以及醫療保健提供者的日益普及。
  • 根據給藥途徑，2024 年腸外給藥佔市場主導地位。注射劑型，尤其是靜脈注射和皮下注射 G-CSF，由於與口服給藥相比起效更快、生物有效性更高，仍然是主要的給藥方式。
  • 從分銷管道來看，由於醫院化療的普及率較高，醫院藥局在 2024 年佔據了最大的市場佔有率。醫院藥局是 CIN 治療的主要來源，確保關鍵藥物的即時供應和管理。
  • 由於完善的醫療基礎設施、較高的癌症意識和先進的治療選擇，北美在 CIN 治療市場處於領先地位。該地區對研究和創新的高度重視進一步推動了市場成長。

目錄

第1章調查方法與範圍

第2章執行摘要

第3章化療嗜中性白血球低下症治療市場變數、趨勢和範圍

  • 市場體系展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 商業環境分析
    • 產業分析—波特五力分析
    • PESTLE分析
    • 管道分析
    • 定價分析

第4章化療引起的嗜中性白血球低下症治療市場：治療業務分析

  • 2024年和2030年的治療市場佔有率
  • 治療細分儀表板
  • 市場規模、預測與趨勢分析（按治療，2018-2030 年）
  • 生長因子
  • 抗生素
  • 抗真菌劑
  • 其他

第5章化療嗜中性白血球低下症治療市場：製藥業務分析

  • 2024年及2030年的醫藥市場佔有率
  • 藥品細分儀表板
  • 市場規模、預測與趨勢分析（按藥物，2018-2030 年）
  • 品牌藥品
  • 生物相似藥

第6章化療嗜中性白血球低下症治療市場：給藥途徑業務分析

  • 2024 年及 2030 年給藥途徑市場佔有率
  • 給藥途徑細分儀表板
  • 按管理路線分類的市場規模、預測和趨勢分析（2018-2030 年）
  • 腸外
  • 口服

第7章化療引起的嗜中性白血球低下症治療市場：分銷通路業務分析

  • 2024年及2030年分銷通路市場佔有率
  • 分銷通路細分儀表板
  • 按分銷管道分類的市場規模、預測和趨勢分析（2018-2030 年）
  • 醫院藥房
  • 零售藥局
  • 網路藥局

第8章化療嗜中性白血球低下症治療市場：按地區估計和趨勢分析

  • 2024 年及 2030 年區域市場佔有率分析
  • 區域市場儀表板
  • 2018-2030年市場規模及預測趨勢分析
  • 北美洲
    • 2018-2030年各國情況
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第9章競爭格局

  • 參與者概述
  • 企業市場分析
  • 公司分類
  • 戰略地圖
  • 公司簡介/上市公司
    • Amgen Inc.
    • Sandoz
    • Teva Pharmaceutical Industries Ltd
    • Coherus BioSciences Inc.
    • Coherus BioSciences Inc.
    • Viatris Inc.
    • Biocon Biologics Inc.
    • Pfizer Inc.
    • Spectrum Pharmaceuticals, Inc.
    • Evive BIoTech
    • G1 Therapeutics, Inc.
Product Code: GVR-4-68040-198-8

Chemotherapy-induced Neutropenia Treatment Market Growth & Trends:

The global chemotherapy-induced neutropenia treatment market is anticipated to reach USD 1.51 billion by 2030 and is expected to decline at a CAGR of -0.48% from 2025 to 2030, according to a new report by Grand View Research, Inc. This decline can be attributed to multiple factors, including the growing adoption of targeted cancer therapies and immunotherapies, which reduce the incidence of chemotherapy-induced neutropenia (CIN) compared to traditional chemotherapy. As precision medicine advances, oncologists are increasingly shifting towards treatment modalities that minimize myelosuppressive effects, thereby reducing the demand for CIN treatments. However, the rise of home healthcare and self-administrable therapies also presents an opportunity for pharmaceutical companies to develop user-friendly formulations that improve patient convenience.

Chemotherapy-Induced Neutropenia (CIN), a severe side effect of cancer treatment, poses significant risks for patients undergoing chemotherapy. As the prevalence of cancer cases continues to rise, the demand for effective CIN treatments is driving substantial growth in the healthcare sector. Businesses are capitalizing on advancements in treatment modalities, novel drug developments, and improved patient care solutions to address this critical condition. The market is witnessing increased investments in growth factors, antibiotics, antifungal agents, and other supportive therapies, ensuring better management of CIN and reducing associated complications.

To combat CIN effectively, growth factors play a vital role in stimulating white blood cell production, reducing the risk of infections in affected patients. Granulocyte Colony-Stimulating Factors (G-CSFs) are the primary treatment option, enhancing neutrophil recovery and minimizing chemotherapy delays. Leading pharmaceutical companies such as Amgen Inc., Sandoz, Teva Pharmaceutical Industries Ltd., Coherus BioSciences, Viatris Inc., and Biocon Biologics Inc. are at the forefront of G-CSF development.

Filgrastim is a widely used recombinant G-CSF that accelerates neutrophil recovery. Pegfilgrastim, a longer-acting version of Filgrastim, reduces the frequency of administration, while Lipegfilgrastim offers sustained neutrophil stimulation. Eflapegrastim is a novel, long-acting G-CSF providing effective prophylaxis against CIN, and Efbemalenograstim alfa is a next-generation therapy under development for enhanced neutrophil support. Additionally, Granulocyte-Macrophage Colony-Stimulating Factors (GM-CSFs) are expanding the therapeutic potential in neutrophil recovery. Key market players, including Pfizer Inc., Spectrum Pharmaceuticals, Inc., Evive Biotech, and G1 Therapeutics, Inc., are actively investing in research and development to improve the efficacy of these treatments.

However, even with the use of growth factors, CIN patients remain highly susceptible to bacterial and fungal infections, making the use of prophylactic and therapeutic antibiotics crucial. Prophylactic antibiotics play a key role in preventing infections in high-risk patients, while therapeutic antibiotics are administered when infections develop. Similarly, antifungal agents help combat opportunistic infections, ensuring comprehensive patient care. These treatments collectively form a multi-layered defense system against the risks posed by CIN. Prophylactic antibiotics serve as a preventive measure to reduce infection rates in neutropenic patients, whereas therapeutic antibiotics help manage bacterial infections that arise due to the weakened immune system. Meanwhile, antifungal agents provide an added layer of protection against invasive fungal infections, which can be life-threatening for patients undergoing chemotherapy.

In addition to these conventional treatment options, emerging therapies such as granulocyte transfusions and immunomodulatory agents are gaining attention as potential solutions for severe cases of neutropenia. Ongoing research and innovation are expected to enhance the effectiveness and accessibility of these treatment options, further strengthening the market landscape. The CIN treatment market is divided into branded drugs and biosimilars. Branded drugs continue to dominate due to their established efficacy, but biosimilars are rapidly gaining traction due to their cost-effectiveness and increasing adoption. As regulatory approvals expand and healthcare accessibility improves, biosimilar options are becoming more widely available, allowing more patients to benefit from advanced therapies without the financial burden of high-priced branded drugs.

Along with the development of new drug options, treatment delivery methods are also evolving. Parenteral administration remains the gold standard for CIN management, with intravenous (IV) and subcutaneous (SC) routes being preferred for G-CSFs and antibiotics to ensure rapid and effective results. However, oral options for prophylactic antibiotics and immunomodulatory agents are gaining popularity, offering greater convenience for outpatient care. This shift in administration methods aligns with the broader healthcare trend of enhancing patient accessibility and reducing hospital dependency for chronic care management.

As the burden of cancer continues to grow worldwide, the CIN treatment market is poised for substantial expansion. The increasing adoption of biosimilars, continuous advancements in drug development, and ongoing research into innovative therapies are collectively shaping the future of CIN management. With enhanced awareness, improved treatment protocols, and growing investment in supportive care, the future of CIN treatment is set to witness significant progress. These developments not only ensure better patient outcomes but also contribute to the overall advancement of global healthcare solutions.

Chemotherapy-induced Neutropenia Treatment Market Report Highlights:

  • On the basis of treatment, the growth factors segment dominated the market in 2024. The segment's dominance is attributable to its proven efficacy, widespread adoption in cancer treatment protocols, and continuous advancements in biosimilars.
  • Biosimilars led the drug type segment in market in 2024, driven by increasing regulatory approvals, cost-effectiveness, and growing adoption by healthcare providers..
  • On the basis of the route of administration, the parenteral segment dominated the market in 2024. Injectable formulations, particularly intravenous and subcutaneous G-CSFs, remain the primary mode of administration due to the rapid onset of their action and higher bioavailability compared to oral alternatives.
  • On the basis of distribution channel, the hospital pharmacies segment held the largest market share in 2024, driven by the high volume of chemotherapy conducted in hospital settings. Hospital pharmacies are the primary source of CIN treatment drugs, ensuring immediate availability and administration of critical medications
  • North America led the CIN treatment market, attributed to factors such as a well-established healthcare infrastructure, high awareness of cancer, and the availability of advanced treatment options. The region's strong focus on research and innovation further supports market growth.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Treatment
    • 1.2.2. Drug
    • 1.2.3. Route of Administration
    • 1.2.4. Distribution Channel
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Distribution Channel & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Chemotherapy-Induced Neutropenia (CIN) Treatment Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis
      • 3.3.3.1. Phase 1
      • 3.3.3.2. Phase 2
      • 3.3.3.3. Phase 3
    • 3.3.4. Pricing Analysis

Chapter 4. Chemotherapy-Induced Neutropenia (CIN) Treatment Market: Treatment Business Analysis

  • 4.1. Treatment Market Share, 2024 & 2030
  • 4.2. Treatment Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Treatment, 2018 to 2030 (USD Million)
  • 4.4. Growth Factors
    • 4.4.1. Growth Factors Market, 2018 - 2030 (USD Million)
  • 4.5. Antibiotics
    • 4.5.1. Antibiotics Market, 2018 - 2030 (USD Million)
  • 4.6. Antifungal Agents
    • 4.6.1. Antifungal Agents Market, 2018 - 2030 (USD Million)
  • 4.7. Other Treatments
    • 4.7.1. Other Treatments Market, 2018 - 2030 (USD Million)

Chapter 5. Chemotherapy-Induced Neutropenia (CIN) Treatment Market: Drug Business Analysis

  • 5.1. Drug Market Share, 2024 & 2030
  • 5.2. Drug Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Drug, 2018 to 2030 (USD Million)
  • 5.4. Branded Drugs
    • 5.4.1. Branded Drugs Market, 2018 - 2030 (USD Million)
  • 5.5. Biosimilars
    • 5.5.1. Biosimilars Market, 2018 - 2030 (USD Million)

Chapter 6. Chemotherapy-Induced Neutropenia (CIN) Treatment Market: Route of Administration Business Analysis

  • 6.1. Route of Administration Market Share, 2024 & 2030
  • 6.2. Route of Administration Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by Route of Administration, 2018 to 2030 (USD Million)
  • 6.4. Parenteral
    • 6.4.1. Parenteral Market, 2018 - 2030 (USD Million)
  • 6.5. Oral
    • 6.5.1. Oral Market, 2018 - 2030 (USD Million)

Chapter 7. Chemotherapy-Induced Neutropenia (CIN) Treatment Market: Distribution Channel Business Analysis

  • 7.1. Distribution Channel Market Share, 2024 & 2030
  • 7.2. Distribution Channel Segment Dashboard
  • 7.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Million)
  • 7.4. Hospital Pharmacies
    • 7.4.1. Hospital Pharmacies Market, 2018 - 2030 (USD Million)
  • 7.5. Retail Pharmacies
    • 7.5.1. Retail Pharmacies Market, 2018 - 2030 (USD Million)
  • 7.6. Online Pharmacies
    • 7.6.1. Online Pharmacies Market, 2018 - 2030 (USD Million)

Chapter 8. Chemotherapy-Induced Neutropenia (CIN) Treatment Market: Regional Estimates & Trend Analysis

  • 8.1. Regional Market Share Analysis, 2024 & 2030
  • 8.2. Regional Market Dashboard
  • 8.3. Market Size & Forecasts Trend Analysis, 2018 to 2030:
  • 8.4. North America
    • 8.4.1. North America Chemotherapy-Induced Neutropenia (CIN) Treatment Market Estimates and Forecasts, By Country, 2018 - 2030 (USD Million)
    • 8.4.2. U.S.
      • 8.4.2.1. Key Country Dynamics
      • 8.4.2.2. Target Disease Prevalence
      • 8.4.2.3. Regulatory Framework
      • 8.4.2.4. Reimbursement Framework
      • 8.4.2.5. U.S. Chemotherapy-Induced Neutropenia (CIN) Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.3. Canada
      • 8.4.3.1. Key Country Dynamics
      • 8.4.3.2. Target Disease Prevalence
      • 8.4.3.3. Regulatory Framework
      • 8.4.3.4. Reimbursement Framework
      • 8.4.3.5. U.S. Chemotherapy-Induced Neutropenia (CIN) Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.4. Mexico
      • 8.4.4.1. Key Country Dynamics
      • 8.4.4.2. Target Disease Prevalence
      • 8.4.4.3. Regulatory Framework
      • 8.4.4.4. Reimbursement Framework
      • 8.4.4.5. Mexico Chemotherapy-Induced Neutropenia (CIN) Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5. Europe
    • 8.5.1. Europe Chemotherapy-Induced Neutropenia (CIN) Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.2. UK
      • 8.5.2.1. Key Country Dynamics
      • 8.5.2.2. Target Disease Prevalence
      • 8.5.2.3. Regulatory Framework
      • 8.5.2.4. Reimbursement Framework
      • 8.5.2.5. Uk Chemotherapy-Induced Neutropenia (CIN) Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.3. Germany
      • 8.5.3.1. Key Country Dynamics
      • 8.5.3.2. Target Disease Prevalence
      • 8.5.3.3. Regulatory Framework
      • 8.5.3.4. Reimbursement Framework
      • 8.5.3.5. Germany Chemotherapy-Induced Neutropenia (CIN) Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.4. France
      • 8.5.4.1. Key Country Dynamics
      • 8.5.4.2. Target Disease Prevalence
      • 8.5.4.3. Regulatory Framework
      • 8.5.4.4. Reimbursement Framework
      • 8.5.4.5. France Chemotherapy-Induced Neutropenia (CIN) Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.5. Italy
      • 8.5.5.1. Key Country Dynamics
      • 8.5.5.2. Target Disease Prevalence
      • 8.5.5.3. Regulatory Framework
      • 8.5.5.4. Reimbursement Framework
      • 8.5.5.5. Italy Chemotherapy-Induced Neutropenia (CIN) Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.6. Spain
      • 8.5.6.1. Key Country Dynamics
      • 8.5.6.2. Target Disease Prevalence
      • 8.5.6.3. Regulatory Framework
      • 8.5.6.4. Reimbursement Framework
      • 8.5.6.5. Spain Chemotherapy-Induced Neutropenia (CIN) Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.7. Denmark
      • 8.5.7.1. Key Country Dynamics
      • 8.5.7.2. Target Disease Prevalence
      • 8.5.7.3. Regulatory Framework
      • 8.5.7.4. Reimbursement Framework
      • 8.5.7.5. Denmark Chemotherapy-Induced Neutropenia (CIN) Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.8. Sweden
      • 8.5.8.1. Key Country Dynamics
      • 8.5.8.2. Target Disease Prevalence
      • 8.5.8.3. Regulatory Framework
      • 8.5.8.4. Reimbursement Framework
      • 8.5.8.5. Sweden Chemotherapy-Induced Neutropenia (CIN) Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.9. Norway
      • 8.5.9.1. Key Country Dynamics
      • 8.5.9.2. Target Disease Prevalence
      • 8.5.9.3. Regulatory Framework
      • 8.5.9.4. Reimbursement Framework
      • 8.5.9.5. Norway Chemotherapy-Induced Neutropenia (CIN) Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6. Asia Pacific
    • 8.6.1. Asia Pacific Chemotherapy-Induced Neutropenia (CIN) Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.2. Japan
      • 8.6.2.1. Key Country Dynamics
      • 8.6.2.2. Target Disease Prevalence
      • 8.6.2.3. Regulatory Framework
      • 8.6.2.4. Reimbursement Framework
      • 8.6.2.5. Japan Chemotherapy-Induced Neutropenia (CIN) Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.3. China
      • 8.6.3.1. Key Country Dynamics
      • 8.6.3.2. Target Disease Prevalence
      • 8.6.3.3. Regulatory Framework
      • 8.6.3.4. Reimbursement Framework
      • 8.6.3.5. China Chemotherapy-Induced Neutropenia (CIN) Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.4. India
      • 8.6.4.1. Key Country Dynamics
      • 8.6.4.2. Target Disease Prevalence
      • 8.6.4.3. Regulatory Framework
      • 8.6.4.4. Reimbursement Framework
      • 8.6.4.5. India Chemotherapy-Induced Neutropenia (CIN) Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.5. Australia
      • 8.6.5.1. Key Country Dynamics
      • 8.6.5.2. Target Disease Prevalence
      • 8.6.5.3. Regulatory Framework
      • 8.6.5.4. Reimbursement Framework
      • 8.6.5.5. Australia Chemotherapy-Induced Neutropenia (CIN) Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.6. South Korea
      • 8.6.6.1. Key Country Dynamics
      • 8.6.6.2. Target Disease Prevalence
      • 8.6.6.3. Regulatory Framework
      • 8.6.6.4. Reimbursement Framework
      • 8.6.6.5. South Korea Chemotherapy-Induced Neutropenia (CIN) Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.7. Thailand
      • 8.6.7.1. Key Country Dynamics
      • 8.6.7.2. Target Disease Prevalence
      • 8.6.7.3. Regulatory Framework
      • 8.6.7.4. Reimbursement Framework
      • 8.6.7.5. Thailand Chemotherapy-Induced Neutropenia (CIN) Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.7. Latin America
    • 8.7.1. Latin America Chemotherapy-Induced Neutropenia (CIN) Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.7.2. Brazil
      • 8.7.2.1. Key Country Dynamics
      • 8.7.2.2. Target Disease Prevalence
      • 8.7.2.3. Regulatory Framework
      • 8.7.2.4. Reimbursement Framework
      • 8.7.2.5. Japan Chemotherapy-Induced Neutropenia (CIN) Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.7.3. Argentina
      • 8.7.3.1. Key Country Dynamics
      • 8.7.3.2. Target Disease Prevalence
      • 8.7.3.3. Regulatory Framework
      • 8.7.3.4. Reimbursement Framework
      • 8.7.3.5. China Chemotherapy-Induced Neutropenia (CIN) Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.8. Middle East and Africa
    • 8.8.1. Middle East and Africa Chemotherapy-Induced Neutropenia (CIN) Treatment Market Estimates and Forecasts, 2017 - 2030 (USD Million)
    • 8.8.2. South Africa
      • 8.8.2.1. Key Country Dynamics
      • 8.8.2.2. Target Disease Prevalence
      • 8.8.2.3. Regulatory Framework
      • 8.8.2.4. Reimbursement Framework
      • 8.8.2.5. South Africa Chemotherapy-Induced Neutropenia (CIN) Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.8.3. Saudi Arabia
      • 8.8.3.1. Key Country Dynamics
      • 8.8.3.2. Target Disease Prevalence
      • 8.8.3.3. Regulatory Framework
      • 8.8.3.4. Reimbursement Framework
      • 8.8.3.5. Saudi Arabia Chemotherapy-Induced Neutropenia (CIN) Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.8.4. UAE
      • 8.8.4.1. Key Country Dynamics
      • 8.8.4.2. Target Disease Prevalence
      • 8.8.4.3. Regulatory Framework
      • 8.8.4.4. Reimbursement Framework
      • 8.8.4.5. UAE Chemotherapy-Induced Neutropenia (CIN) Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.8.5. Kuwait
      • 8.8.5.1. Key Country Dynamics
      • 8.8.5.2. Target Disease Prevalence
      • 8.8.5.3. Regulatory Framework
      • 8.8.5.4. Reimbursement Framework
      • 8.8.5.5. Kuwait Chemotherapy-Induced Neutropenia (CIN) Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Participant Overview
  • 9.2. Company Market Position Analysis
  • 9.3. Company Categorization
  • 9.4. Strategy Mapping
  • 9.5. Company Profiles/Listing
    • 9.5.1. Amgen Inc.
      • 9.5.1.1. Overview
      • 9.5.1.2. Financial Performance
      • 9.5.1.3. Product Benchmarking
      • 9.5.1.4. Strategic Initiatives
    • 9.5.2. Sandoz
      • 9.5.2.1. Overview
      • 9.5.2.2. Financial Performance
      • 9.5.2.3. Product Benchmarking
      • 9.5.2.4. Strategic Initiatives
    • 9.5.3. Teva Pharmaceutical Industries Ltd
      • 9.5.3.1. Overview
      • 9.5.3.2. Financial Performance
      • 9.5.3.3. Product Benchmarking
      • 9.5.3.4. Strategic Initiatives
    • 9.5.4. Coherus BioSciences Inc.
      • 9.5.4.1. Overview
      • 9.5.4.2. Financial Performance
      • 9.5.4.3. Product Benchmarking
      • 9.5.4.4. Strategic Initiatives
    • 9.5.5. Coherus BioSciences Inc.
      • 9.5.5.1. Overview
      • 9.5.5.2. Financial Performance
      • 9.5.5.3. Product Benchmarking
      • 9.5.5.4. Strategic Initiatives
    • 9.5.6. Viatris Inc.
      • 9.5.6.1. Overview
      • 9.5.6.2. Financial Performance
      • 9.5.6.3. Product Benchmarking
      • 9.5.6.4. Strategic Initiatives
    • 9.5.7. Biocon Biologics Inc.
      • 9.5.7.1. Overview
      • 9.5.7.2. Financial Performance
      • 9.5.7.3. Product Benchmarking
      • 9.5.7.4. Strategic Initiatives
    • 9.5.8. Pfizer Inc.
      • 9.5.8.1. Overview
      • 9.5.8.2. Financial Performance
      • 9.5.8.3. Product Benchmarking
      • 9.5.8.4. Strategic Initiatives
    • 9.5.9. Spectrum Pharmaceuticals, Inc.
      • 9.5.9.1. Overview
      • 9.5.9.2. Financial Performance
      • 9.5.9.3. Product Benchmarking
      • 9.5.9.4. Strategic Initiatives
    • 9.5.10. Evive Biotech
      • 9.5.10.1. Overview
      • 9.5.10.2. Financial Performance
      • 9.5.10.3. Product Benchmarking
      • 9.5.10.4. Strategic Initiatives
    • 9.5.11. G1 Therapeutics, Inc.
      • 9.5.11.1. Overview
      • 9.5.11.2. Financial Performance
      • 9.5.11.3. Product Benchmarking
      • 9.5.11.4. Strategic Initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Global Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Region, 2018 - 2030 (USD Million)
  • Table 4 Global Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 5 Global Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 6 Global Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 7 Global Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 8 North America Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Country, 2018 - 2030 (USD Million)
  • Table 9 North America Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 10 North America Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 11 North America Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 12 North America Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 13 U.S. Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 14 U.S. Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 15 U.S. Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 16 U.S. Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 17 Canada Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 18 Canada Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 19 Canada Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 20 Canada Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 21 Mexico Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 22 Mexico Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 23 Mexico Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 24 Mexico Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 25 Europe Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Country, 2018 - 2030 (USD Million)
  • Table 26 Europe Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 27 Europe Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 28 Europe Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 29 Europe Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 30 UK Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 31 UK Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 32 UK Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 33 UK Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 34 Germany Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 35 Germany Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 36 Germany Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 37 Germany Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 38 France Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 39 France Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 40 France Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 41 France Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 42 Italy Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 43 Italy Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 44 Italy Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 45 Italy Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 46 Italy Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 47 Spain Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 48 Spain Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 49 Spain Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 50 Spain Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 51 Norway Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 52 Norway Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 53 Norway Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 54 Norway Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 55 Denmark Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 56 Denmark Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 57 Denmark Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 58 Denmark Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 59 Sweden Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 60 Sweden Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 61 Sweden Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 62 Sweden Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 63 Asia Pacific Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Country, 2018 - 2030 (USD Million)
  • Table 64 Asia Pacific Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 65 Asia Pacific Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 66 Asia Pacific Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 67 Asia Pacific Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 68 Japan Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 69 Japan Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 70 Japan Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 71 Japan Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 72 China Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 73 China Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 74 China Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 75 China Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 76 India Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 77 India Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 78 India Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 79 India Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 80 Australia Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 81 Australia Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 82 Australia Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 83 Australia Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 84 South Korea Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 85 South Korea Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 86 South Korea Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 87 South Korea Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 88 Thailand Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 89 Thailand Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 90 Thailand Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 91 Thailand Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 92 Latin America Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Country, 2018 - 2030 (USD Million)
  • Table 93 Latin America Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 94 Latin America Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 95 Latin America Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 96 Latin America Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 97 Brazil Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 98 Brazil Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 99 Brazil Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 100 Brazil Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 101 Argentina Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 102 Argentina Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 103 Argentina Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 104 Argentina Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 105 Middle East & Africa Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Country, 2018 - 2030 (USD Million)
  • Table 106 Middle East & Africa Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 107 Middle East & Africa Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 108 Middle East & Africa Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 109 Middle East & Africa Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 110 South Africa Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 111 South Africa Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 112 South Africa Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 113 South Africa Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 114 Saudi Arabia Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 115 Saudi Arabia Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 116 Saudi Arabia Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 117 Saudi Arabia Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 118 UAE Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 119 UAE Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 120 UAE Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 121 UAE Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 122 Kuwait Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 123 Kuwait Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 124 Kuwait Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 125 Kuwait Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Chemotherapy-induced neutropenia (CIN) treatment market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value chain-based sizing & forecasting
  • Fig. 7 QFD modelling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 Market snapshot
  • Fig. 10 Treatment and Drug snapshot
  • Fig. 11 Route of administration and distribution channel snapshot
  • Fig. 12 Competitive landscape snapshot
  • Fig. 13 Parent market value, 2024 (USD billion)
  • Fig. 14 Market dynamics
  • Fig. 15 Porter's five forces analysis
  • Fig. 16 PESTLE analysis
  • Fig. 17 Chemotherapy-induced neutropenia (CIN) treatment market: Treatment outlook and key takeaways
  • Fig. 18 Chemotherapy-induced neutropenia (CIN) treatment market: Treatment movement analysis
  • Fig. 19 Growth factors market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 20 Antibiotics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 21 Antifungal agents market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 22 Other treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 23 Chemotherapy-induced neutropenia (CIN) treatment market: Drug outlook and key takeaways
  • Fig. 24 Chemotherapy-induced neutropenia (CIN) treatment market: Drug movement analysis
  • Fig. 25 Branded drugs market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 26 Biosimilar market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 27 Chemotherapy-induced neutropenia (CIN) treatment market: Route of administration outlook and key takeaways
  • Fig. 28 Chemotherapy-induced neutropenia (CIN) treatment market: Route of administration movement analysis
  • Fig. 29 Parenteral market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 30 Oral market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 31 Chemotherapy-induced neutropenia (CIN) treatment market: Distribution channel market outlook and key takeaways
  • Fig. 32 Chemotherapy-induced neutropenia (CIN) treatment market: Distribution channel market movement analysis
  • Fig. 33 Hospital pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 34 Retail pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 35 Online pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 36 Chemotherapy-induced neutropenia (CIN) treatment market revenue, by region, 2024 & 2030 (USD Million)
  • Fig. 37 Regional marketplace: Key takeaways
  • Fig. 38 North America chemotherapy-induced neutropenia (CIN) treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 Key country dynamics
  • Fig. 40 U.S. chemotherapy-induced neutropenia (CIN) treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 Cancer incidence, 2022 - 2045
  • Fig. 42 U.S. healthcare system: money flow
  • Fig. 43 Key country dynamics
  • Fig. 44 Canada chemotherapy-induced neutropenia (CIN) treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 Cancer incidence, 2022 - 2045
  • Fig. 46 Key country dynamics
  • Fig. 47 Mexico chemotherapy-induced neutropenia (CIN) treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Cancer incidence, 2022 - 2045
  • Fig. 49 Regulatory framework
  • Fig. 50 Europe chemotherapy-induced neutropenia (CIN) treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Key country dynamics
  • Fig. 52 UK chemotherapy-induced neutropenia (CIN) treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 Cancer incidence, 2022 - 2045
  • Fig. 54 Key country dynamics
  • Fig. 55 Germany chemotherapy-induced neutropenia (CIN) treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 56 Cancer incidence, 2022 - 2045
  • Fig. 57 Exclusivity formula
  • Fig. 58 Germany insurance coverage
  • Fig. 59 Key country dynamics
  • Fig. 60 France chemotherapy-induced neutropenia (CIN) treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 Cancer incidence, 2022 - 2045
  • Fig. 62 Key country dynamics
  • Fig. 63 Italy chemotherapy-induced neutropenia (CIN) treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 64 Cancer incidence, 2022 - 2045
  • Fig. 65 Key country dynamics
  • Fig. 66 Spain chemotherapy-induced neutropenia (CIN) treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 67 Cancer incidence, 2022 - 2045
  • Fig. 68 Key country dynamics
  • Fig. 69 Denmark chemotherapy-induced neutropenia (CIN) treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 70 Cancer Incidence, 2022 - 2045
  • Fig. 71 Key country dynamics
  • Fig. 72 Sweden chemotherapy-induced neutropenia (CIN) treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 73 Cancer incidence 2022 - 2045
  • Fig. 74 Key country dynamics
  • Fig. 75 Norway chemotherapy-induced neutropenia (CIN) treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 76 Cancer incidence, 2022 - 2045
  • Fig. 77 Rest of Europe chemotherapy-induced neutropenia (CIN) treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 78 Asia Pacific chemotherapy-induced neutropenia (CIN) treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 79 Key country dynamics
  • Fig. 80 Japan chemotherapy-induced neutropenia (CIN) treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 81 Cancer incidence, 2022 - 2045
  • Fig. 82 Japan pharmaceutical registration
  • Fig. 83 Key country dynamics
  • Fig. 84 China chemotherapy-induced neutropenia (CIN) treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 85 Cancer incidence, 2022 - 2045
  • Fig. 86 Regulatory details: China
  • Fig. 87 Key country dynamics
  • Fig. 88 India chemotherapy-induced neutropenia (CIN) treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 89 Cancer incidence, 2018 - 2030
  • Fig. 90 Key country dynamics
  • Fig. 91 Australia chemotherapy-induced neutropenia (CIN) treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 92 Cancer incidence, 2018 - 2030
  • Fig. 93 Key country dynamics
  • Fig. 94 Thailand chemotherapy-induced neutropenia (CIN) treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 95 Cancer incidence, 2018 - 2030
  • Fig. 96 Key country dynamics
  • Fig. 97 South Korea chemotherapy-induced neutropenia (CIN) treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 98 Cancer incidence, 2018 - 2030
  • Fig. 99 Rest of Asia Pacific chemotherapy-induced neutropenia (CIN) treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 100 Latin America chemotherapy-induced neutropenia (CIN) treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 101 Key country dynamics
  • Fig. 102 Brazil chemotherapy-induced neutropenia (CIN) treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 103 Cancer incidence, 2018 - 2030
  • Fig. 104 Key country dynamics
  • Fig. 105 Argentina chemotherapy-induced neutropenia (CIN) treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 106 Cancer incidence, 2018 - 2030
  • Fig. 107 Rest of Latin America chemotherapy-induced neutropenia (CIN) treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 108 MEA chemotherapy-induced neutropenia (CIN) treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 109 Key country dynamics
  • Fig. 110 South Africa chemotherapy-induced neutropenia (CIN) treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 111 Cancer incidence, 2018 - 2030
  • Fig. 112 Key country dynamics
  • Fig. 113 Saudi Arabia chemotherapy-induced neutropenia (CIN) treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 114 Cancer incidence, 2018 - 2030
  • Fig. 115 Key country dynamics
  • Fig. 116 UAE chemotherapy-induced neutropenia (CIN) treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 117 Cancer incidence, 2018 - 2030
  • Fig. 118 Key country dynamics
  • Fig. 119 Kuwait chemotherapy-induced neutropenia (CIN) treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 120 Cancer incidence, 2018 - 2030
  • Fig. 121 Rest of MEA chemotherapy-induced neutropenia (CIN) treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 122 Company/competition categorization
  • Fig. 123 Strategy mapping